Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $8.00 Consensus Price Target from Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have received an average rating of “Hold” from the five research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $8.00.

Several research analysts have weighed in on MIST shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Wall Street Zen upgraded Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Finally, Zacks Research lowered Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th.

Insider Buying and Selling at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 34,523 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $66,629.39. Following the completion of the sale, the chief executive officer directly owned 482,744 shares in the company, valued at approximately $931,695.92. The trade was a 6.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 113,693 shares of company stock valued at $233,347. 19.50% of the stock is currently owned by insiders.

Institutional Trading of Milestone Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Creative Planning raised its holdings in shares of Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares during the period. XTX Topco Ltd boosted its holdings in shares of Milestone Pharmaceuticals by 209.5% in the 2nd quarter. XTX Topco Ltd now owns 160,963 shares of the company’s stock valued at $312,000 after buying an additional 108,959 shares during the period. Raymond James Financial Inc. grew its position in shares of Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after buying an additional 10,000 shares during the last quarter. Valeo Financial Advisors LLC grew its position in shares of Milestone Pharmaceuticals by 553.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock valued at $254,000 after buying an additional 110,699 shares during the last quarter. Finally, Sapient Capital LLC acquired a new stake in Milestone Pharmaceuticals during the third quarter worth about $25,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Performance

Shares of MIST opened at $1.31 on Monday. The firm has a market cap of $154.15 million, a price-to-earnings ratio of -1.66 and a beta of 0.69. The company has a quick ratio of 7.96, a current ratio of 8.01 and a debt-to-equity ratio of 1.37. The business’s 50 day moving average is $1.67 and its two-hundred day moving average is $1.96. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Friday, March 20th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $37.52 million. Analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.